Evidence map›Paper›PMID 29775793›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2019

Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-Grade Dysplasia in Patients With Inflammatory Bowel Disease.

John B Kisiel, Pasquale Klepp, Hatim T Allawi, William R Taylor, Maria Giakoumopoulos, Tamara Sander, Tracy C Yab, Bjorn A Moum, Graham P Lidgard, Stephan Brackmann and 3 more

Abstract read
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. DNA methylation in necrotizing enterocolitis.Expert reviews in molecular medicine · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. COVID-19: Colorectal cancer endoscopic surveillance in IBD.The lancet. Gastroenterology & hepatology · 2021
    Article
  17. Review
  18. Article
  19. A gut butyrate-producing bacteriumOncology letters · 2020
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

John B KisielDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: kisiel.john@mayo.edu.
Pasquale KleppDepartment of Internal Medicine, Lovisenberg Hospital, Oslo, Norway; Clinical Medicine, University Hospital, University of Oslo, Oslo, Norway.
Hatim T AllawiDepartment of Gastroenterology, Akershus University Hospital, University of Oslo, Oslo, Norway.
William R TaylorDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Maria GiakoumopoulosExact Sciences Corporation, Madison, Wisconsin.
Tamara SanderExact Sciences Corporation, Madison, Wisconsin.
Tracy C YabDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Bjorn A MoumDepartment of Gastroenterology, Oslo University Hospital, Oslo, Norway.
Graham P LidgardExact Sciences Corporation, Madison, Wisconsin.
Stephan BrackmannDepartment of Gastroenterology, Akershus University Hospital, University of Oslo, Oslo, Norway; Clinical Medicine, University Hospital, University of Oslo, Oslo, Norway.
Douglas W MahoneyDepartment of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Arne RosethDepartment of Internal Medicine, Lovisenberg Hospital, Oslo, Norway.
David A AhlquistDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Mayo Clinic · USExact Sciences (United States) · USOslo University Hospital · NOLovisenberg Diakonale Høgskole · NOUniversity of Oslo · NO

Funding

Paul Calabresi Program in Clinical/Translational Research at Mayo ClinicK12CA090628 · NCI · MAYO CLINIC ROCHESTER · PI WEROHA, SARAVUT · 2001 to 2025
$19.7M
Multi-site Gastrointestinal Cancer Detection by Stool DNA MethylationR37CA214679 · NCI · MAYO CLINIC ROCHESTER · PI KISIEL, JOHN · 2018 to 2024
$2.8M
Multi-cancer Early DetectionR01CA214679 · NCI · MAYO CLINIC ROCHESTER · PI John Kisiel, Niloy Jewel Samadder · 2025 to 2026
$891k
NCI NIH HHS K12 CA090628NCI NIH HHS R01 CA214679NCI NIH HHS R37 CA214679
6 · The paper itself

Abstract

BACKGROUND &

aimsPatients with inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, are at increased risk for colorectal cancer (CRC). Analyses of DNA methylation patterns in stool samples have been reported to detect CRC in patients with IBD. We sought to validate these findings in larger cohorts and assess the accuracy of analysis of DNA methylation patterns in stool for detection of CRC and high-grade dysplasia (HGD) normalized to methylation level at ZDHHC1.

methodsWe obtained buffered, frozen stool samples from a US case-control study and from 2 European surveillance cohorts (referral or population based) of patients with chronic ulcerative colitis (n = 248), Crohn's disease (n = 82), indeterminate colitis (n = 2), or IBD with primary sclerosing cholangitis (n = 38). Stool samples were collected before bowel preparation for colonoscopy or at least 1 week after colonoscopy. Among the study samples, stools from individuals with IBD but without neoplasia were used as controls (n = 291). DNA was isolated from stool, exposed to bisulfite, and then assayed by multiplex quantitative allele-specific real-time target and signal amplification. We analyzed methylation levels of BMP3, NDRG4, VAV3, and SFMBT2 relative to the methylation level of ZDHHC1, and compared these between patients with CRC or HGD and controls.

resultsLevels of methylation at BMP3 and VAV3, relative to ZDHHC1 methylation, identified patients with CRC and HGD with an area under the curve value of 0.91 (95% CI, 0.77-1.00). Methylation levels at specific promotor regions of these genes identified 11 of the 12 patients with CRC and HGD, with 92% sensitivity (95% CI, 60%-100%) and 90% specificity (95% CI, 86%-93%). The proportion of false-positive results did not differ significantly among the case-control, referral cohort, and population cohort studies (P = .60) when the 90% specificity cut-off from the whole sample set was applied.

conclusionsIn an analysis of stool samples from 3 independent studies of 332 patients with IBD, we associated levels of methylation at 2 genes (BMP3 and VAV3), relative to level of methylation at ZDHHC1, with detection of CRC and HGD. These methylation patterns identified patients with CRC and HGD with more than 90% specificity, and might be used in CRC surveillance.

Indexed as

DNA MethylationAdultAgedColorectal NeoplasmsDNAFecesFemaleHumansInflammatory Bowel DiseasesMaleMiddle AgedPathology, MolecularSensitivity and SpecificityDNABiomarkerComplicationsNeoplasmNoninvasive TestPrevention

Identifiers

PMID29775793
PMCPMC6368476
OpenAlexW2803701657

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.